

University of Dundee

**Circulating plasma concentrations of ACE2 in men and women with heart failure and effects of renin-angiotensin-aldosterone-inhibitors**

Sama, Izhah E.; Ravera, Alice; Santema, Bernadet T.; van Goor, Harry; ter Maaten, Jozine M.; Cleland, John G. F.

*Published in:*  
European Heart Journal

*DOI:*  
[10.1093/eurheartj/ehaa373](https://doi.org/10.1093/eurheartj/ehaa373)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Sama, I. E., Ravera, A., Santema, B. T., van Goor, H., ter Maaten, J. M., Cleland, J. G. F., Rienstra, M., Friedrich, A. W., Samani, N. J., Ng, L. L., Dickstein, K., Lang, C. C., Filippatos, G., Anker, S. D., Ponikowski, P., Metra, M., van Veldhuisen, D. J., & Voors, A. A. (2020). Circulating plasma concentrations of ACE2 in men and women with heart failure and effects of renin-angiotensin-aldosterone-inhibitors. *European Heart Journal*, 41(19), 1810-1817. <https://doi.org/10.1093/eurheartj/ehaa373>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

- 1 **Supplemental Table 3:** Baseline characteristics according to quartiles of plasma ACE2 concentrations for patients not on
- 2 RAAS-inhibitors (validation cohort)

	Q1[2.60,4.83)	Q2[4.83,5.26)	Q3[5.26,5.79)	Q4[5.79,8.46]	p-value	N
	<i>N=86</i>	<i>N=86</i>	<i>N=95</i>	<i>N=112</i>		
<b>Validation Cohort</b>						
ACE2 concentrations	4.54 [4.34;4.71]	5.07 [4.97;5.18]	5.50 [5.37;5.63]	6.33 [6.09;6.69]	<0.001	379
Sex:					<0.001	379
Men	39 (45.3%)	45 (52.3%)	63 (66.3%)	81 (72.3%)		
Women	47 (54.7%)	41 (47.7%)	32 (33.7%)	31 (27.7%)		
Age (years)	77.5 [70.0;83.0]	79.5 [71.0;85.0]	80.0 [74.0;84.5]	81.0 [73.0;86.0]	0.266	379
Body mass index (kg/m <sup>2</sup> )	27.8 [24.5;33.2]	25.7 [22.7;29.5]	27.1 [24.6;32.0]	27.1 [23.0;29.9]	0.064	368
Heart rate (beats/minute)	74.5 [62.2;84.8]	77.0 [65.0;84.0]	71.5 [65.5;85.5]	75.0 [63.0;87.0]	0.866	372

	Q1[2.60,4.83)	Q2[4.83,5.26)	Q3[5.26,5.79)	Q4[5.79,8.46]	p-value	N
	N=86	N=86	N=95	N=112		
Systolic blood pressure (mmHg)	125 [112;141]	124 [106;140]	125 [111;141]	122 [107;138]	0.619	375
Left ventricular ejection fraction	47.0 [40.0;60.0]	45.0 [37.5;53.0]	45.0 [35.0;52.5]	43.0 [35.0;52.0]	0.061	350
New York Heart Association (NYHA) class:					.	379
Class I	0 (0.00%)	1 (1.16%)	0 (0.00%)	0 (0.00%)		
Class II	30 (34.9%)	26 (30.2%)	29 (30.5%)	32 (28.6%)		
Class III	41 (47.7%)	32 (37.2%)	44 (46.3%)	54 (48.2%)		
Class IV	15 (17.4%)	27 (31.4%)	22 (23.2%)	26 (23.2%)		
History of Atrial fibrillation	34 (40.0%)	29 (34.1%)	44 (46.3%)	53 (47.7%)	0.214	376
Renal disease	42 (48.8%)	39 (46.4%)	55 (57.9%)	65 (58.6%)	0.229	376
Diabetes	21 (25.0%)	29 (33.7%)	35 (36.8%)	33 (29.7%)	0.353	376
Hypertension	52 (60.5%)	49 (57.0%)	61 (65.6%)	60 (53.6%)	0.354	377

	Q1[2.60,4.83)	Q2[4.83,5.26)	Q3[5.26,5.79)	Q4[5.79,8.46]	p-value	N
	N=86	N=86	N=95	N=112		
Chronic obstructive pulmonary disease	16 (18.8%)	22 (25.6%)	20 (21.1%)	25 (22.5%)	0.751	377
Myocardial infarction	33 (38.4%)	38 (44.2%)	47 (49.5%)	54 (48.2%)	0.430	379
Ischemic HF aetiology	52 (94.5%)	55 (94.8%)	67 (93.1%)	73 (97.3%)	0.701	260
Coronary artery disease	40 (47.6%)	46 (53.5%)	55 (57.9%)	60 (54.1%)	0.589	376
Coronary artery by-pass graft	12 (14.0%)	9 (10.5%)	15 (15.8%)	23 (20.7%)	0.250	378
Percutaneous coronary intervention	9 (11.0%)	14 (16.3%)	17 (18.1%)	17 (15.6%)	0.613	371
Use of Angiotensin Converting Enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB): No	86 (100%)	86 (100%)	95 (100%)	112 (100%)	.	379
Beta-blockers	56 (65.1%)	50 (58.1%)	62 (65.3%)	69 (61.6%)	0.730	379
ACE inhibitors: No	86 (100%)	86 (100%)	95 (100%)	112 (100%)	.	379
ARBs: No	86 (100%)	86 (100%)	95 (100%)	112 (100%)	.	379

	Q1[2.60,4.83)	Q2[4.83,5.26)	Q3[5.26,5.79)	Q4[5.79,8.46]	p-value	N
	<i>N=86</i>	<i>N=86</i>	<i>N=95</i>	<i>N=112</i>		
Mineralocorticoid Receptor Antagonist (MRA): No	86 (100%)	86 (100%)	95 (100%)	112 (100%)	.	379
ACE inhibitors and MRA: no ACEi and no MRA	86 (100%)	86 (100%)	95 (100%)	112 (100%)	.	379

1